MicroRNA-106 a在非小细胞肺癌中的表达及意义

摘要

目的：：探讨微小RNA-106a(miRNA-106a)在非小细胞肺癌(NSCLC)中的表达情况，并进一步分析其与肿瘤的临床病理特征和预后的相关性。方法：收集42例NSCLC肿瘤组织和相对应的正常肺组织，采用RT-PCR方法检测miRNA-106a在组织中的相对表达量，同时在肺癌细胞株和正常支气管上皮细胞中加以验证。进一步分析miRNA-106a的表达与临床病理资料和预后的相关性。结果：肺癌组织中miR-106a表达水平(3.72±1.81)明显高于正常肺组织(1.15±0.52)(P<0.01)；肺腺癌A549细胞和鳞癌SK-MES-1细胞中miR-106a的表达水平均高于正常人支气管上皮16HBE细胞，差异具有显著统计学意义(P<0.01)。 MiR-106a的表达水平与肺癌的EGFR基因突变、淋巴结转移及临床分期明显相关(P<0.05)。 MiR-106a低表达者生存时间明显高于高表达组(P<0.01)。结论：MiR-106a在NSCLC肿瘤组织中表达上调，可作为NSCLC预后判断的潜在分子标志物。%Objective:To investigate the expression of microRNA-106a( miR-106a) in patients with non-small cell lung cancer( NSCLC) and to analyze the relationships between miR-106a and clinicopathological features and prognosis. Methods:The expression level of miR-106a in 42 tumor tissues and paired normal tissues of NSCLC were detected by RT-PCR. The expression level of miR-106a in lung cancer cells and bronchial epithelial cells was detec-ted by RT-PCR. The relationships between the level of miR-106a in cancer tissues and the pathological characteris-tics and prognosis were analyzed. Results:The expression level of miR-106a was up-regulated in tumor tissues as compared with the paired normal lung tissues(P<0. 05). The similar pattern was also seen in A549 cells and SK-MES-1 cells. The expression of miR-106a in tumor tissues was associated with lymphatic metastasis,TNM stages and mutation of EGFR(P<0. 05). Conclusion:The low expression of miR-106a have longer overall survival than high ex-pression of miR-106a in tumor tissues(P<0. 05).